New cell therapy trial offers hope for patients with aggressive blood cancers
NCT ID NCT06730256
Summary
This early-phase study is testing a new type of cell therapy called CT0596 CAR-T in patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to better target cancer, and then infuse them back into the patient. The main goals are to see if the treatment is safe, determine the best dose, and check if it can shrink the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.